AngioDynamics (ANGO) Q3 2026: MedTech Revenue Jumps 19% as Portfolio Shift Accelerates
AngioDynamics’ third consecutive guidance raise underscores the momentum behind its MedTech-led transformation. With MedTech now nearly half of total revenue, the company’s focused execution is delivering sustained growth and operating leverage, despite tariff and supply chain headwinds. Forward visibility remains high as the company leans into differentiated platforms and clinical adoption, while cash discipline and portfolio realignment continue to reshape risk and opportunity.
Summary
- MedTech Outpaces Legacy Device: Rapid MedTech expansion is reshaping the revenue base and margin profile.
- Portfolio Execution Drives Guidance Raise: Three straight quarters of raised outlook signal consistent outperformance.
- Strategic Shift Sustains Growth Trajectory: Platform wins and clinical adoption provide durable tailwinds into 2027.
Performance Analysis
AngioDynamics delivered another quarter of broad-based growth, with total revenue up 8.9% and MedTech segment revenue surging 19% year over year. The MedTech segment now comprises 48% of total revenue, up from 44% last year, illustrating a deliberate and continuing shift away from legacy MedDevice lines toward higher-margin, innovation-driven platforms.
Within MedTech, the Arion platform, laser atherectomy technology, posted its 19th consecutive quarter of double-digit growth, while AlphaVac, mechanical thrombectomy device, revenue soared 47% year over year, driving the segment’s sequential acceleration. NanoKnife, ablation system, also posted strong 21% growth, with probe sales in prostate care and new capital placements both contributing. The MedDevice segment, now a cash-generative but slow-growth anchor, increased just 1.1%, reinforcing the strategic pivot toward MedTech. Gross margin compressed by 110 basis points to 52.9%, primarily due to tariffs and manufacturing transition costs, partially offset by favorable product mix and pricing initiatives.
- MedTech Mix Shift: MedTech’s share of total revenue rose to 48%, up 400 basis points year over year, reflecting ongoing portfolio transformation.
- AlphaVac Momentum: AlphaVac delivered its strongest sequential revenue increase since launch, driven by new account wins and increased utilization.
- Margin Pressure from Tariffs: Tariff expense of $1.3 million weighed on gross margin, with full-year tariff headwind expected between $4 and $6 million.
Operating leverage is beginning to emerge as SG&A held steady as a percentage of sales, and adjusted EBITDA improved year over year despite inflation and tariff pressures.
Executive Commentary
"We maintained our trend of driving top line growth, led by impressive growth in our MedTech segment. Beyond the top line, we continue to deliver strong profitability by expanding our adjusted EBITDA. Our performance continues to show that our strategy to drive profitable growth in our high-margin, large medtech markets is working."
Jim Clemmer, President and Chief Executive Officer
"Our MedTech platforms comprised 48% of our total revenue compared to 44% of total revenue a year ago, reflecting the ongoing shift in our business mix. This year-over-year improvement is largely attributable to our MedTech revenue growth and the success of our gross margin and operating efficiency initiatives. We've done all this while absorbing tariff costs that were not there a year ago."
Steve Trowbridge, Executive Vice President and Chief Financial Officer
Strategic Positioning
1. MedTech-Led Portfolio Realignment
AngioDynamics is methodically executing a shift from legacy, slow-growth MedDevice lines to high-margin, innovation-driven MedTech platforms. Recent divestitures and product discontinuations have sharpened the focus on differentiated technologies, supporting both growth and margin expansion.
2. Platform Differentiation and Clinical Adoption
Arion’s sustained double-digit growth and AlphaVac’s accelerating adoption highlight the company’s ability to win share through clinical performance and physician engagement. The hospital channel is now a key growth engine, with ongoing investments in product extensions and training programs driving utilization and customer loyalty.
3. Regulatory and Market Access Catalysts
Regulatory milestones, such as CE mark approvals and CPT-1 reimbursement for NanoKnife, are expanding addressable markets and supporting international growth. The APEX return pivotal trial for AlphaVac is expected to further accelerate adoption by broadening indications and clinical evidence.
4. Resilient Operating Model and Cash Discipline
Despite macro and supply chain headwinds, AngioDynamics maintains a strong balance sheet with zero debt. Proactive inventory management ahead of sterilization vendor shutdowns, and clear communication on cash flow dynamics, reinforce a disciplined approach to risk and capital allocation.
5. Leadership Transition and Continuity
With a CEO succession process underway, the board has engaged a search firm to ensure continuity in strategic and financial initiatives. The leadership team remains focused on seamless execution and stakeholder alignment during the transition period.
Key Considerations
This quarter’s results reflect a business in the midst of a successful transformation, with MedTech driving both financial and strategic momentum. The company’s ability to absorb inflationary and tariff pressures while raising guidance signals operational resilience and market share gains.
Key Considerations:
- MedTech Growth Engine: Arion and AlphaVac platforms are delivering outsized growth, supported by new account wins and positive physician feedback.
- Margin Management: Tariff and inflation headwinds are being actively managed through pricing and product mix, though gross margin remains sensitive to external cost shocks.
- Cash Flow Timing: Proactive inventory build ahead of sterilization shutdowns will temporarily pressure cash flow, but underlying cash generation remains intact.
- Portfolio Rationalization: Recent divestitures and product discontinuations have streamlined operations and sharpened focus on core growth drivers.
- Leadership Continuity: CEO transition process is underway, with clear interim leadership and ongoing execution of strategic initiatives.
Risks
Tariff, inflation, and energy cost volatility remain material risks to margin stability, as acknowledged by management and reflected in guidance. Supply chain disruptions, including sterilization vendor shutdowns, could impact inventory and cash flow if not managed proactively. Competitive intensity in mechanical thrombectomy and reimbursement dynamics for NanoKnife remain watchpoints for future quarters. Leadership transition introduces some uncertainty, though the process appears well-structured.
Forward Outlook
For Q4, AngioDynamics guided to:
- Net sales of $313.5 to $315.5 million for FY26 (up from $312 to $314 million prior)
- MedTech segment growth of 15% to 17%, MedDevice growth of approximately 1%
For full-year 2026, management raised guidance:
- Adjusted EBITDA of $10 to $12 million (from $8 to $10 million prior)
- Gross margin of 53.5% to 55.5%, inclusive of $4 to $6 million tariff impact
- Adjusted loss per share of $0.30 to $0.23 (improved from $0.33 to $0.23)
Management highlighted several factors that will shape the outlook:
- Continued sequential growth in AlphaVac and Arion driven by account expansion and clinical adoption
- Temporary cash flow impact from inventory build to offset sterilization vendor downtime, with full-year cash generation profile unchanged
Takeaways
AngioDynamics’ Q3 results reinforce the durability of its MedTech-led growth strategy, with portfolio execution and clinical adoption translating into sustained revenue and profitability gains. Margin headwinds are being actively managed, and the company’s balance sheet strength provides flexibility for continued investment and risk mitigation.
- Sustained MedTech Momentum: High-margin platform growth is increasingly driving the company’s financial and strategic trajectory, with legacy MedDevice now a secondary contributor.
- Operational Agility: Proactive management of tariffs, inflation, and supply chain disruptions is enabling continued outperformance and guidance raises.
- Visibility into 2027: Platform adoption, regulatory catalysts, and a streamlined portfolio support a constructive multi-year outlook, though leadership transition and external cost pressures remain key watchpoints.
Conclusion
AngioDynamics’ third consecutive guidance raise and accelerating MedTech mix highlight a business executing on a clear strategic vision. With differentiated platforms gaining share and operational discipline intact, the company is positioned for continued growth and margin expansion into fiscal 2027.
Industry Read-Through
AngioDynamics’ results and commentary signal a broader industry shift toward platform-centric, high-margin MedTech portfolios, with legacy device lines increasingly divested or deprioritized. Clinical evidence, hospital channel penetration, and regulatory milestones remain key growth levers across the sector. Tariff and inflation pressures are a persistent margin risk for all device manufacturers, while proactive supply chain and inventory management are now baseline expectations for operational resilience. Investors should expect continued consolidation and portfolio rationalization across the medical device landscape as companies seek to replicate AngioDynamics’ mix shift and margin expansion playbook.